Literature DB >> 17646939

[Surgical ablation therapy - lessons learned].

A Diegeler1.   

Abstract

Atrial fibrillation (AF) is the most frequent sustained arrhythmia affecting more than 5% of the population above 65 years resulting in loss in quality of life and life expectancy. Since the introduction of the MAZE procedure, an increasing number of surgical approaches have been implemented for the treatment of AF. During past years a variety of devices such as application of unipolar and bipolar radiofrequency, cryothermal therapy, microwave, laser and ultrasound have been described. All new methods have undergone thorough evaluations; in that course technical systems have been re-designed and surgical approaches were modified. Before reaching a widespread clinical application a thorough analysis in terms of therapeutic benefit and possible complications is required. Several reports have reported success rates leading to reinstitution of atrial rhythm in 60 to 80% of the patients treated. However, there is no overview on possible complications using surgical ablation therapy. In this report we have focused on different energy sources, time of occurrence of postoperative arrhythmias, patient's symptoms and related diagnostic processes. Various published reports of surgical ablation therapy were evaluated with regard to complications that have occurred. In addition, our own extensive experience was considered as well.

Entities:  

Mesh:

Year:  2007        PMID: 17646939     DOI: 10.1007/s00399-007-0568-7

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  27 in total

Review 1.  Pathophysiology and prevention of atrial fibrillation.

Authors:  M A Allessie; P A Boyden; A J Camm; A G Kléber; M J Lab; M J Legato; M R Rosen; P J Schwartz; P M Spooner; D R Van Wagoner ; A L Waldo
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

Review 2.  Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation.

Authors:  N R Grubb; S Furniss
Journal:  BMJ       Date:  2001-03-31

3.  Myocardial infarction after cryoablation surgery for Wolff-Parkinson-White syndrome.

Authors:  Hiroshi Watanabe; Jun-ichi Hayashi; Yoshifusa Aizawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-05

4.  Myocardial infarction after a maze procedure for idiopathic atrial fibrillation.

Authors:  T Sueda; H Shikata; N Mitsui; H Nagata; Y Matsuura
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

5.  Coronary artery stenosis after radiofrequency catheter ablation of accessory atrioventricular pathways in children with Ebstein's malformation.

Authors:  H Bertram; R Bökenkamp; M Peuster; G Hausdorf; T Paul
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

Review 6.  The epidemiology of atrial fibrillation.

Authors:  M J Domanski
Journal:  Coron Artery Dis       Date:  1995-02       Impact factor: 1.439

7.  Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs.

Authors:  Kaori Shinagawa; Yan-Fen Shi; Jean-Claude Tardif; Tack-Ki Leung; Stanley Nattel
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

8.  Efficacy of a simple left atrial procedure for chronic atrial fibrillation in mitral valve operations.

Authors:  T Sueda; H Nagata; K Orihashi; S Morita; K Okada; M Sueshiro; S Hirai; Y Matsuura
Journal:  Ann Thorac Surg       Date:  1997-04       Impact factor: 4.330

9.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

10.  Esophageal perforation during left atrial radiofrequency ablation: Is the risk too high?

Authors:  Nicolas Doll; Michael A Borger; Alexander Fabricius; Susann Stephan; Jan Gummert; Friedrich W Mohr; Johann Hauss; Hans Kottkamp; Gerd Hindricks
Journal:  J Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.